Payment overview · 2025
General Payments
$936.17
46 reported records · 18 companies
Healthcare provider profile · identity verified
Afshan Hameeduddin, MD
Allopathic & Osteopathic Physicians|Family Medicine · SCHAUMBURG, IL · NPI 1992884084
Verified facts
What the public records show
CMS Open Payments records show Afshan Hameeduddin, MD received $936.17 in general payments during 2025 across 46 reported records.
PFIZER INC. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Linzess, Mounjaro, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 366 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1038 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $171.56 | 18.3% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $99.17 | 10.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $83.13 | 8.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.30 | 8.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.51 | 8.1% | 3 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $60.48 | 6.5% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $52.29 | 5.6% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $45.72 | 4.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.54 | 4.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.85 | 3.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.37 | 3.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.30 | 3.5% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $30.95 | 3.3% | 1 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $27.64 | 3.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.22 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.32 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.86 | 1.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.96 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $936.17 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $132.54 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $108.75 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $83.13 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.81 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $62.81 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.71 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $61.77 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $61.77 | 2 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $60.48 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $52.29 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $45.72 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.54 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.30 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $30.95 | 1 | 2025 |
Source payment records
|
|||||
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Oral Health Care Undivided Normalized: oral health care undivided |
Device | Philips North America LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1038 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 85 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
85 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
36 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
366 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1038 | 117 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2069 | 287 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1888 | 230 |
| Omeprazole | Omeprazole | 1236 | 163 |
| Furosemide | Furosemide | 1148 | 163 |
| Gabapentin | Gabapentin | 1040 | 140 |
| Eliquis | Apixaban | 1038 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 1037 | 176 |
| Pantoprazole Sodium | Pantoprazole Sodium | 999 | 164 |
| Metoprolol Tartrate | Metoprolol Tartrate | 833 | 126 |
| Metformin Hcl | Metformin Hcl | 743 | 116 |
| Lisinopril | Lisinopril | 715 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 710 | 94 |
| Potassium Chloride | Potassium Chloride | 702 | 107 |
| Losartan Potassium | Losartan Potassium | 674 | 114 |
| Carvedilol | Carvedilol | 655 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 639 | 97 |
| Sertraline Hcl | Sertraline Hcl | 537 | 82 |
| Famotidine | Famotidine | 512 | 58 |
| Quetiapine Fumarate | Quetiapine Fumarate | 507 | 74 |
| Bumetanide | Bumetanide | 475 | 70 |
| Donepezil Hcl | Donepezil Hcl | 451 | 61 |
| Montelukast Sodium | Montelukast Sodium | 407 | 48 |
| Simvastatin | Simvastatin | 400 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 378 | 68 |
| Levetiracetam | Levetiracetam | 375 | 39 |
| Jardiance | Empagliflozin | 366 | 47 |
| Mirtazapine | Mirtazapine | 365 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 340 | 50 |
| Risperidone | Risperidone | 339 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 323 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 314 | 50 |
| Memantine Hcl | Memantine Hcl | 309 | 47 |
| Allopurinol | Allopurinol | 299 | 39 |
| Spironolactone | Spironolactone | 296 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 288 | 39 |
| Baclofen | Baclofen | 278 | 33 |
| Trazodone Hcl | Trazodone Hcl | 278 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 46 |
| Enulose | Lactulose | 219 | 29 |
| Januvia | Sitagliptin Phosphate | 219 | 35 |
| Divalproex Sodium | Divalproex Sodium | 216 | 36 |
| Alendronate Sodium | Alendronate Sodium | 214 | 30 |
| Finasteride | Finasteride | 210 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 203 | 19 |
| Buspirone Hcl | Buspirone Hcl | 189 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 29 |
| Warfarin Sodium | Warfarin Sodium | 170 | 23 |
| Xarelto | Rivaroxaban | 165 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 161 | 44 |
| Lamotrigine | Lamotrigine | 160 | 16 |
| Latanoprost | Latanoprost | 156 | 24 |
| Propranolol Hcl | Propranolol Hcl | 155 | 17 |
| Carbamazepine | Carbamazepine | 154 | 11 |
| Cephalexin | Cephalexin | 147 | 78 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 18 |
| Aripiprazole | Aripiprazole | 145 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 139 | 24 |
| Azithromycin | Azithromycin | 134 | 101 |
| Benztropine Mesylate | Benztropine Mesylate | 128 | 13 |
| Atenolol | Atenolol | 122 | 13 |
| Tramadol Hcl | Tramadol Hcl | 118 | 39 |
| Prednisone | Prednisone | 117 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 16 |
| Midodrine Hcl | Midodrine Hcl | 107 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 107 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 106 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 104 | 22 |
| Glipizide | Glipizide | 101 | 18 |
| Lovastatin | Lovastatin | 99 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 99 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 99 | 56 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 11 |
| Myrbetriq | Mirabegron | 96 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 96 | 17 |
| Glimepiride | Glimepiride | 93 | 12 |
| Primidone | Primidone | 93 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 92 | 75 |
| Amiodarone Hcl | Amiodarone Hcl | 91 | 15 |
| Bethanechol Chloride | Bethanechol Chloride | 91 | 19 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 89 | 21 |
| Metformin Hcl Er | Metformin Hcl | 86 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 57 |
| Linzess | Linaclotide | 85 | suppressed |
| Tradjenta | Linagliptin | 85 | suppressed |
| Olanzapine | Olanzapine | 84 | 19 |
| Topiramate | Topiramate | 84 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 82 | 18 |
| Vancomycin Hcl | Vancomycin Hcl | 82 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 81 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 81 | 13 |
| Gemfibrozil | Gemfibrozil | 81 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 80 | suppressed |
| Nystatin | Nystatin | 80 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 79 | 21 |
| Digoxin | Digoxin | 77 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 59 |
| Nifedipine Er | Nifedipine | 75 | 16 |
| Nyamyc | Nystatin | 75 | 25 |
| Ezetimibe | Ezetimibe | 71 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 12 |
| Lorazepam | Lorazepam | 67 | 34 |
| Divalproex Sodium Er | Divalproex Sodium | 66 | suppressed |
| Ketoconazole | Ketoconazole | 66 | 27 |
| Meloxicam | Meloxicam | 65 | 16 |
| Oxcarbazepine | Oxcarbazepine | 65 | suppressed |
| Valsartan | Valsartan | 64 | suppressed |
| Alprazolam | Alprazolam | 62 | 22 |
| Entresto | Sacubitril/Valsartan | 60 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 60 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 58 | 14 |
| Lokelma | Sodium Zirconium Cyclosilicate | 58 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 15 |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Ozempic | Semaglutide | 55 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 53 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 28 |
| Tobramycin Sulfate | Tobramycin Sulfate | 51 | suppressed |
| Clonazepam | Clonazepam | 49 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 35 |
| Ibuprofen | Ibuprofen | 48 | 32 |
| Gemtesa | Vibegron | 46 | suppressed |
| Levemir Flexpen | Insulin Detemir | 46 | suppressed |
| Levocarnitine | Levocarnitine | 46 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | suppressed |
| Methylprednisolone | Methylprednisolone | 45 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 44 | suppressed |
| Sulfasalazine | Sulfasalazine | 44 | suppressed |
| Amoxicillin | Amoxicillin | 43 | 32 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 43 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 43 | suppressed |
| Lidocaine | Lidocaine | 43 | 13 |
| Nystop | Nystatin | 43 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 12 |
| Clozapine | Clozapine | 42 | suppressed |
| Calcitriol | Calcitriol | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 29 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 40 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Lacosamide | Lacosamide | 40 | suppressed |
| Colchicine | Colchicine | 39 | suppressed |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Anastrozole | Anastrozole | 36 | suppressed |
| Carbamazepine Er | Carbamazepine | 36 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 36 | suppressed |
| Prolia | Denosumab | 36 | 20 |
| Novolog Flexpen | Insulin Aspart | 35 | 15 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 35 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Brilinta | Ticagrelor | 34 | suppressed |
| Felodipine Er | Felodipine | 34 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 16 |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Phenytoin | Phenytoin | 33 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 20 |
| Scopolamine | Scopolamine | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 26 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | 22 |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Diazepam | Diazepam | 28 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 11 |
| Acyclovir | Acyclovir | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Restasis | Cyclosporine | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | 14 |
| Torsemide | Torsemide | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 24 | 24 |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 20 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Mirabegron Er | Mirabegron | 23 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Admelog Solostar | Insulin Lispro | 21 | suppressed |
| Levocarnitine Sf | Levocarnitine | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 20 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Cryselle | Norgestrel-Ethinyl Estradiol | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 19 | 16 |
| Trimethoprim | Trimethoprim | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Leflunomide | Leflunomide | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 13 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 14 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Mupirocin | Mupirocin | 16 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Permethrin | Permethrin | 14 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Denta 5000 Plus | Fluoride (Sodium) | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $936.17 · 46 records | PFIZER INC. | AIRSUPRA, AUSTEDO XR, ArdeoGraft, Briviact, CAPLYTA, CREON, ELIQUIS, EVENITY, INGREZZA, LINZESS, MOUNJARO, NURTEC ODT, Oral Health Care Undivided, PelloGraft, QULIPTA, REPATHA, REXULTI, RenoGraft, SurGraft, SurMatrix, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, XIFAXAN, Xelstrym, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error